Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis

What Was Tested

This randomized controlled trial paper looks at Kisspeptin-10 and Kisspeptin-54.

The aim of this study was to determine the effects of acute and chronic kisspeptin administration on gonadotropin release in women with HA.

Why It Was Studied

Kisspeptin is a critical regulator of normal reproductive function.

A single injection of kisspeptin in healthy human volunteers potently stimulates gonadotropin release.

Who Took Part

The age groups tagged for this paper are young adults and adults, women only.

Changes in serum gonadotropin and estradiol levels, LH pulsatility, and ultrasound measurements of reproductive activity were assessed.

How the Study Was Run

The design is described as randomized, double-blind and parallel-group.

The participants were allocated by chance, so the Kisspeptin-10 group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Kisspeptin-10.

The Kisspeptin-10 group and the comparison group ran side by side rather than switching.

The researchers performed a prospective, randomized, double-blinded, parallel design study.

What Was Measured

The subject headings attached to it are Amenorrhea, Body Mass Index, Follicle Stimulating Hormone, Gonadotropins, Hypothalamus, Kisspeptins and Luteinizing Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Kisspeptin-10 and Kisspeptin-54.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Kisspeptin-10 compound page and the Kisspeptin-54 compound page.